NMRA实时信号 | 通过Getagraph.com最大化利润

购买 107909 min ago

@ $18.19

发出时间: 15 Feb 2024 @ 01:07

回报率: -48.65%

上一信号: Feb 15 - 00:05

上一信号: 出售

回报率: -1.41 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 23:36):

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases...

Stats
今日成交量	40 137.00
平均成交量	569 314
市值	1.48B
EPS	$0 ( 2024-03-13 )
下一个收益日期	( $-0.350 ) 2024-06-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.57
ATR14	$0.0260 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-08	Arch Venture Partners Xii, Llc	Buy	1 176 593	Common Stock
2023-12-08	Arch Venture Partners Xii, Llc	Buy	703 061	Common Stock
2023-12-08	Arch Venture Partners X, Llc	Buy	1 176 593	Common Stock
2023-12-08	Arch Venture Partners X, Llc	Buy	703 061	Common Stock
2023-12-08	Burow Kristina	Buy	1 176 593	Common Stock

INSIDER POWER
35.63
Last 85 transactions
Buy: 48 806 253 \| Sell: 23 661 663

音量相关性

長: -0.50 (neutral)

短: 0.04 (neutral)

Signal:(39.494) Neutral

Neumora Therapeutics, 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Neumora Therapeutics, 相关性 - 货币/商品

-0.83
( strong negative )

-0.89
( strong negative )

0.00
( neutral )

-0.53
( weak negative )

0.43
( neutral )

0.87
( strong )

Neumora Therapeutics, 财务报表

Annual	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-0.860

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-0.860

Financial Reports:

No articles found.

Neumora Therapeutics,

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.